Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.

Almirall, J; Betancourt, L; Esteve, V; Valenzuela, M P; López, T; Ruiz, A; Martínez-Ocaña, J C; Calvet, X

Almirall, J; Betancourt, L; Esteve, V; Valenzuela, M P; López, T; Ruiz, A; Martínez-Ocaña, J C; Calvet, X.

Affiliation

Almirall J; Departament de Medicina (UAB), Nephrology Service, Corporació Parc Taulí, Institut Universitari Parc Taulí, Sabadell, Spain. jalmirall@tauli.cat

Int Urol Nephrol ; 44(1): 231-6, 2012 Feb.

Article in En | MEDLINE | ID: mdl-21069570

Subject(s)

Chelating Agents/therapeutic use; Hyperphosphatemia/drug therapy; Kidney Failure, Chronic/blood; Lanthanum/therapeutic use; Phosphates/blood; Aged; Chelating Agents/adverse effects; Dyspepsia/etiology; Female; Humans; Hyperphosphatemia/etiology; Kidney Failure, Chronic/complications; Kidney Failure, Chronic/therapy; Lanthanum/adverse effects; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Renal Dialysis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phosphates / Chelating Agents / Hyperphosphatemia / Kidney Failure, Chronic / Lanthanum Type of study: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Int Urol Nephrol Year: 2012 Document type: Article Affiliation country: Spain Country of publication: Netherlands

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google